CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, nurses, radiologic oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.
  
  LEARNING OBJECTIVES

  • Recognize the frequency with which BRCA1/2 and other homologous recombination repair mutations are present in patients with prostate cancer, and develop a rational clinical algorithm to guide the use of genetic testing.
  • Assess the pharmacologic, pharmacodynamic and pharmacokinetic similarities and differences among the approved and investigational PARP inhibitors for prostate cancer to better understand the activity and toxicities of these agents.
  • Develop an understanding of the rationale for and available data with PARP inhibitors in combination with androgen receptor (AR) pathway inhibitors in preparation for the potential clinical availability of these regimens.
  • Recognize the side effects associated with PARP inhibitors alone and in combination with AR pathway inhibitors in the treatment of prostate cancer, and develop strategies to prevent, mitigate and manage toxicities.
  • Counsel appropriately selected patients with prostate cancer about clinical trial opportunities attempting to further define the role of PARP inhibitors in combination with agents targeting the AR pathway.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Neeraj Agarwal, MD, FASCO
  Professor of Medicine
  Senior Director for Clinical Translation
  Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research
  Director, Center of Investigational Therapeutics
  Director, Genitourinary Oncology Program
  Huntsman Cancer Institute, University of Utah (NCI-CCC)
  Salt Lake City, Utah
  
  No relevant conflicts of interest to disclose.
  
  Emmanuel S Antonarakis, MD
  Clark Endowed Professor of Medicine
  Division of Hematology, Oncology and Transplantation
  University of Minnesota
  Minneapolis, Minnesota
  
  Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck Sanofi, Tempus; Consulting Agreement: Aadi Bioscience, AIkido Pharma Inc, Blue Earth Diagnostics, CM Propel, Corcept Therapeutics EcoR1 Capital LLC, Foundation Medicine, Hookipa Pharma Inc, Ismar Healthcare NV, KeyQuest Health, MacroGenics Inc, Menarini Group UroWebinar, z-Alpha; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, MorphoSys Orion, Sanofi; Patent Holder: QIAGEN.
  
  Prof Karim Fizazi, MD, PhD
  Head of Service and Full Professor
  Institut Gustave Roussy
  University of Paris Saclay
  Villejuif, France
  
  Advisory Committee: Arvinas, CureVac, Orion Corporation; Data and Safety Monitoring Board/Committee: Lilly; Consulting Agreements (with My Institution): Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Sanofi.
  
  Susan F Slovin, MD, PhD
  Attending Physician, Member
  Genitourinary Oncology Service
  Sidney Kimmel Center for Prostate and Urologic Cancers
  Memorial Sloan Kettering Cancer Center
  Professor of Medicine
  Weill Cornell Medical College
  New York, New York
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  These activities are supported by an educational grant from Pfizer Inc.
  
  Release date: August 2023
  Expiration date: August 2024